ALX : Analysis & Opinions

  1. Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx ...

    December 17, 2014
    It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline ...
  2. Alexion Announces New Share Repurchase Program of $500M - Analyst ...

    December 16, 2014
    Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized ...
  3. Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst ...

    December 15, 2014
    Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
  4. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  5. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  6. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  7. Equinix Gets MarkitServ Deal - Analyst Blog

    June 27, 2013
    Equinix Inc. has successfully secured a deal from an over-the counter (OTC) electronic trade processing service provider ...
  8. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  9. Equinix Opens Phase-I of ZH5 - Analyst Blog

    June 10, 2013
    Equinix Inc. recently announced the opening of the first phase of its fifth data center in Zurich, Switzerland.
  10. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  11. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  12. ADTRAN Looks To Rebound From A Pretty Miserable 2012

    April 10, 2013
    ADTRAN badly needs the long-awaited carrier spending recovery to unlock its value.
  13. General Growth Properties and Other Big Movers In Real Estate ...

    January 3, 2013
    It's been a quiet morning for the market. The Nasdaq is unchanged; the S&P 500 remains relatively unchanged; and the ...
  14. Alexion Pharmaceuticals and Other Nasdaq Stocks Making Big Moves ...

    January 2, 2013
    After this morning's trading, the market is looking good. The Nasdaq is trading up 2.3%; the S&P 500 is up 1.8%; and ...
  15. CBRE Group and Other Big Movers In Real Estate Operations on ...

    December 21, 2012
    The morning has been bad for the market. The Nasdaq is trading down 2%; the S&P 500 has slipped 1.9%; and the Dow has ...
  16. NIKE and More Big Movers on the NYSE on December 21, 2012

    December 21, 2012
    This morning has been rocky for the market. The Nasdaq has fallen 2%; the S&P 500 has slipped 1.9%; and the Dow has fallen ...
  17. Alexion Pharmaceuticals and More Big Movers in Healthcare on ...

    December 7, 2012
    So far today, the Nasdaq is down 0.7%, the S&P 500 is unchanged and the Dow is trading up 0.3%. The healthcare sector ...
  18. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  19. Healthcare Stocks, Including Eli Lilly, Making Big Moves on August ...

    August 24, 2012
    The Nasdaq has increased 0.6%, the S&P 500 has risen 0.5% and the Dow has moved up 0.6% on a good day for the market ...
  20. Biggest Healthcare Sector Movers, Including ALXN

    August 3, 2012
    On a good day for the market, the Nasdaq has climbed 2.2%, the S&P 500 has increased 2% and the Dow is up 1.8%. The healthcare ...
  21. Adtran And Its Peers Are Back To "Show Me" Status

    July 12, 2012
    Adtran continues to stagnate with weak carrier spending. I'd be seriously tempted to wait before buying these shares, but ...
  22. The Toughest Big Value Funds Out There

    March 1, 2012
    If you're looking for safety as well as growth from your value funds, there are several criteria you need to keep in mind, ...
  23. Technology Infrastructure Stocks To Watch

    February 28, 2012
    Technology infrastructure in the United States continues to suffer from a lack of investment. With much spending and work ...
  24. 5 Medical Stocks with Healthy Charts

    February 14, 2012
    Within the health-care sector are some companies with a good mix of technical and fundamental promise. However, some are ...
  25. Big Bets on High-Flying Pharma Stock

    February 9, 2012
    Following bullish earnings, Karee Venema of Schaeffer’s Research writes that call buyers are piling in to one biopharmaceutical ...
  26. Should Biotech Investors Go Where Institutions Won't?

    July 7, 2011
    A lack of institutional ownership should be a warning sign for biotech investors.
  27. Under The Radar Picks For America's Poor Infrastructure

    April 25, 2011
    Infrastructure in the United States continues to suffer from a lack of investment. With much spending and work needed to ...
  28. FDA Locked And Loaded For MELA Sciences

    November 16, 2010
    A harsh FDA review sends MELA down sharply before a pivotal panel meeting.
  29. Is The Weitz Value Fund The King Of Omaha?

    May 20, 2009
    The Weitz Value Fund has an astounding track record of outperforming its benchmark. We check out its philosophy and holdings ...
Trading Center